- Stocks
- Pharma & Healthcare
- Hannah Joseph
Hannah Joseph share price
NSE: HANNAHPharma & HealthcareMedical Care Facilities
Hannah Joseph at a glance
With a market capitalisation of ₹220 Cr, it ranks 2211th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 13.9% in FY25. Promoters held 71.28% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹220 CrRank 2211 on NSE
- Price to book
- 0×FY25
- ROE
- 13.9%FY25
- ROCE
- 16.5%FY25
- Debt to equity
- 0.65FY25
- Net profit margin
- 9.3%FY25
- Book value / share
- ₹31.10FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Hannah Joseph financials
| Item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹55 Cr | ₹63 Cr | ₹78 Cr |
| Operating profit | ₹1 Cr | ₹5 Cr | ₹10 Cr |
| Net profit | ₹1 Cr | ₹4 Cr | ₹7 Cr |
| EPS (₹) | ₹0.63 | ₹2.47 | ₹4.32 |
| Cash from operations | ₹21 Cr | ₹8 Cr | ₹20 Cr |
| Total debt | ₹30 Cr | ₹26 Cr | ₹28 Cr |
| Shareholders' equity | ₹35 Cr | ₹46 Cr | ₹52 Cr |
Hannah Joseph shareholding pattern
| Holder | 2 Feb 2026 | 31 Mar 2026 |
|---|---|---|
| Promoters | 68.83% | 71.28% |
| Foreign institutions | 2.39% | 0.56% |
| Domestic institutions | 10.15% | 9.05% |
| Non-institutions | 18.63% | 19.11% |
Hannah Joseph vs peers
The listed Pharma & Healthcare companies nearest to Hannah Joseph by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NATHBIOGENNath Bio-Genes (India) | ₹132.60 | +0.76% | −23.0% | ₹252 Cr | 6.3 | — |
| BDHBDH Industries | — | — | — | ₹252 Cr | — | — |
| NECLIFENectar Lifesciences | ₹11.34 | −0.09% | −16.5% | ₹220 Cr | — | — |
| HANNAHHannah Joseph | — | — | — | ₹220 Cr | — | — |
| SYSCHEMSyschem (India) | — | — | — | ₹214 Cr | — | — |
| ACHYUTAchyut Health | — | — | — | ₹209 Cr | — | — |
| CORALABCoral Labs | — | — | — | ₹196 Cr | — | — |
Ask anything about Hannah Joseph
Pivot answers on the live chart with evidence you can check, and tests strategies against HANNAH's own history. Try: “Why has HANNAH moved over the last three months?” · “Backtest a 50-day moving-average crossover on HANNAH over five years” · “Compare HANNAH with NATHBIOGEN on margins and valuation”
Frequently asked questions about Hannah Joseph
What is the market cap of Hannah Joseph?
Hannah Joseph's market capitalisation is ₹220 Cr (₹220 Cr) at the 22 Oct 2026 close, ranking 2211th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Hannah Joseph?
Return on equity was 13.9% in FY25 and return on capital employed was 16.5% in FY25 (standalone figures).
Is Hannah Joseph a debt-free company?
No. Hannah Joseph's debt-to-equity ratio was 0.65 in FY25, with total debt of ₹28 Cr.
What is the shareholding pattern of Hannah Joseph?
As of 31 Mar 2026: promoters 71.28%, foreign institutions 0.56%, domestic institutions 9.05%, non-institutions 19.11%.
Who are Hannah Joseph's competitors?
The listed Pharma & Healthcare companies closest to Hannah Joseph by market cap are Nath Bio-Genes (India), BDH Industries, Nectar Lifesciences, Syschem (India), Achyut Health and Coral Labs.
Is Hannah Joseph a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Hannah Joseph's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HANNAH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with H · all NSE stocks · this page as text